编号：2022-003 证券代码：300887 证券简称：谱尼测试 谱尼测试集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------------|---------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | 业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | 其他（电话会议） | | | 活动参与人员 | 详见附件 | | | 时间 | 2022 年 4 月 27 日-5 月 | 6 日 | | 地点 | 电话会议 | | | 上市公司接待 | 董事长 宋薇女士 | | | 人员姓名 | 董事会秘书 李小冬先生 | | | | IR 总监 黄子龙先生 | | | | 一、集团介绍及业绩状况 | 谱尼测试集团作为中国检测行业持续领跑者， 2002 年由国家科研院所 | | | | 改 ...

编号：2022-004 证券代码：300887 证券简称：谱尼测试 谱尼测试集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-006 证券代码：300887 证券简称：谱尼测试 谱尼测试集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | 业绩说明会 | | 投资者关系活动 | □新闻发布会 | 路演活动 | | 类别 | 现场参观 | | | | 其他（电话会议） | | | 活动参与人员 | 详见附件 | | | 时间 | 2022 年 10 月 19 日-11 | 月 7 日 | | 地点 | 北京公司总部、上海、网络会议 | | | 上市公司接待 人员姓名 | ...

Financial Performance - The company's revenue for Q3 2022 reached ¥997,976,762.67, representing a 65.50% increase year-over-year[5] - Net profit attributable to shareholders for the same period was ¥90,036,852.70, up 34.90% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥75,414,064.99, reflecting a 21.09% increase year-over-year[5] - Operating revenue for the first nine months of 2022 reached ¥2,681,962,616.87, a 99.89% increase compared to ¥1,341,708,482.18 in the same period of 2021[11] - Total operating revenue for Q3 2022 reached ¥2,681,962,616.87, a significant increase of 99.5% compared to ¥1,341,708,482.18 in the same period last year[22] - Net profit attributable to shareholders of the parent company was ¥180,717,692.21, compared to ¥93,106,778.91 in Q3 2021, representing a year-over-year growth of 94.0%[23] - The total comprehensive income for the quarter was ¥183,065,632.13, compared to ¥92,995,925.57 in Q3 2021, indicating a growth of 96.8%[23] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥4,583,343,929.17, a 64.83% increase from the end of the previous year[5] - Total liabilities increased to ¥1,180,175,901.11, up from ¥760,684,362.07, reflecting a growth of 55.1%[22] - The company’s equity attributable to shareholders rose by 67.83% to ¥3,390,133,427.18 compared to the previous year-end[5] - The company’s total current assets increased to RMB 2,862,230,878.30 from RMB 1,434,147,384.21, reflecting a growth of approximately 99.6%[19] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥305,336,751.55, showing a significant increase of 385.17%[5] - The total cash inflow from operating activities was CNY 2,563,805,390.75, compared to CNY 1,067,183,500.62 in the previous period, representing an increase of approximately 140%[24] - The net cash flow from operating activities improved by 385.17% to ¥305,336,751.55, compared to a negative cash flow of ¥107,072,623.70 in the previous year[12] - Cash inflow from financing activities surged by 2459.63% to ¥1,549,223,001.44, driven by stock issuance and increased bank loans[12] - The net cash flow from financing activities was CNY 1,155,745,879.45, a turnaround from a negative CNY 3,124,798.93 last year[25] Expenses - Operating costs increased by 137.55% to ¥1,747,644,567.00, primarily due to rising personnel costs and equipment depreciation[11] - R&D expenses rose by 78.40% to ¥183,814,721.27, reflecting increased investment in research and development[11] - Management expenses increased by 30.92% to ¥202,878,439.72, mainly due to the implementation of equity incentives[11] - Research and development expenses for the quarter were ¥183,814,721.27, up 78.1% from ¥103,034,597.59 in the previous year[22] Shareholder Information - The company had a total of 10,155 common shareholders at the end of the reporting period[13] - The largest shareholder, Song Wei, holds 44.85% of the shares, totaling 128,737,800 shares[13] Inventory and Goodwill - The company reported a 168.47% increase in inventory, totaling ¥67,387,596.74, due to increased business volume[9] - The company’s goodwill increased by 117.75% to ¥63,628,233.32, primarily due to the acquisition of a subsidiary[9] - The company’s goodwill increased to RMB 63,628,233.32 from RMB 29,221,284.00, indicating a growth of approximately 117.5%[19]

Financial Performance - The company reported a total revenue of 300 million RMB for the first half of 2022, representing a year-on-year increase of 15%[12]. - The net profit attributable to shareholders was 50 million RMB, up 10% compared to the same period last year[12]. - The company's operating revenue for the reporting period reached ¥1,683,985,854.20, representing a 127.97% increase compared to the same period last year[20]. - Net profit attributable to shareholders was ¥90,680,839.51, a significant increase of 243.94% year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥78,229,124.94, reflecting a 580.50% increase compared to the previous year[20]. - Basic earnings per share rose to ¥0.3532, an increase of 85.89% from ¥0.19 in the same period last year[20]. - The company achieved a total revenue of ¥1,683,985,854.2, representing a year-on-year growth of 127.97%[52]. - The safety assurance segment generated revenue of ¥30,006,981.65, which is a 28.02% increase year-on-year[4]. - The electronic and electrical segment reported revenue of ¥26,614,999.59, reflecting a growth of 24.62% compared to the same period last year[48]. - The company reported a total revenue of 1.5 billion yuan for the first half of 2022, representing a year-over-year increase of 20%[128]. - The company reported a revenue of 500 million in the first half of 2022, representing a year-over-year growth of 25%[130]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% growth in that region by the end of 2023[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[128]. - A strategic acquisition of a local competitor is anticipated to enhance the company's market position and product offerings[128]. - The company is exploring acquisition opportunities to enhance its service offerings and expand its client base[12]. - The company aims to continue its dual-driven growth strategy of "internal growth and acquisitions," focusing on synergistic acquisitions that enhance business collaboration and efficiency[54]. Research and Development - The company has allocated 10% of its revenue towards research and development for new technologies in environmental testing[12]. - Investment in R&D increased by 30% year-over-year, focusing on new technologies and product development[128]. - Research and development expenses rose by 92.96% to ¥106,431,289.05, reflecting the company's commitment to enhancing R&D capabilities[63]. - The company has obtained over 370 authorized patents and more than 150 software copyrights, participating in the formulation of nearly 100 international, national, and industry standards[59]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[4]. - The company faces risks related to brand reputation, market competition, and changes in industry policies, which could impact its operational performance[97][98]. - The company has a strong risk response capability due to its diversified operations across various industries, reducing the impact of economic cycles[30]. Shareholder and Dividend Policies - The company will not distribute cash dividends for this fiscal year, focusing instead on reinvestment for growth[4]. - The company commits to a cash dividend policy, with a minimum cash dividend ratio of 80% for mature stages without significant capital expenditures, and 40% for mature stages with significant expenditures[133]. - The company plans to distribute at least 20% of the distributable profits attributable to the parent company's shareholders in cash annually[133]. - The company will compensate investors for losses incurred due to false statements or omissions in the prospectus[131]. Operational Capacity and Infrastructure - The company operates over 30 large laboratories and more than 150 specialized laboratories across the country, providing comprehensive testing services[31]. - The company has established a comprehensive laboratory and sales network across major regions in China, enabling it to provide high-quality and integrated testing services[49]. - The company has completed acquisitions of Shenzhen Miyo Measurement Testing Co., Ltd. and Chengdu Miyo Measurement Testing Co., Ltd., expanding its medical measurement services in southwestern and southern China[53]. - The company has established several new subsidiaries during the reporting period, which are in the early investment stage and do not significantly impact overall operations and performance[95]. Environmental and Social Responsibility - The company actively participates in environmental protection initiatives, contributing to national and local pollution prevention projects[119]. - The company has become a member of the Shanghai Industrial Carbon Neutrality Service Alliance, collaborating on the implementation of China's "dual carbon" strategy[120]. - The company has been actively fulfilling its social responsibilities and integrating them into its strategic management[113]. Future Guidance - Future guidance indicates a projected revenue growth of 20% for the second half of 2022, driven by increased demand in the healthcare sector[12]. - The company expects a revenue growth of 25% for the second half of 2022, driven by new product launches and market expansion strategies[128]. - The company provided a future outlook, projecting a revenue growth of 30% for the next fiscal year, driven by new product launches and market expansion[130].

Revenue and Profitability - The company's revenue for Q1 2022 reached ¥533,503,557.47, representing a 71.21% increase compared to ¥311,601,470.04 in the same period last year[3] - Net profit attributable to shareholders was ¥5,511,208.06, a significant turnaround from a loss of ¥42,567,499.50 in the previous year, marking a 112.95% improvement[3] - The net profit after deducting non-recurring gains and losses was ¥10,548,370.87, compared to a loss of ¥49,672,628.14 last year, reflecting a 121.24% increase[3] - Operating profit for the quarter was ¥12,681,195.66, compared to an operating loss of ¥41,554,864.98 in the previous year[25] - The company reported a total comprehensive income of ¥5,579,318.07, recovering from a loss of ¥42,569,929.54 in the previous year[26] - The basic and diluted earnings per share were both ¥0.0402, compared to a loss per share of ¥0.3112 in Q1 2021[26] Assets and Liabilities - The total assets at the end of Q1 2022 amounted to ¥4,228,037,046.53, a 52.05% increase from ¥2,780,683,964.60 at the end of the previous year[3] - The company's total equity rose to ¥3,263,155,109.93, compared to ¥2,019,999,602.53 in the previous year, marking a growth of 61.5%[23] - Total liabilities increased to ¥964,881,936.60, up from ¥760,684,362.07 year-on-year, reflecting a growth of 26.8%[23] - The company's total liabilities increased, with accounts payable rising by 49.82% to ¥210,728,412.57, reflecting growth in operational scale[9] Cash Flow - The company's cash flow from operating activities showed an improvement, with a net outflow of ¥75,269,395.38, which is 37.95% less than the outflow of ¥121,307,300.07 in the same period last year[3] - Operating cash inflow for Q1 2022 was $494.09 million, an increase of 64.73% compared to $299.94 million in Q1 2021, primarily due to the collection of receivables[11] - Operating cash outflow for Q1 2022 was $569.36 million, up 35.16% from $421.25 million in Q1 2021, driven by increased payments for goods and services due to business growth[11] - Net cash flow from operating activities improved to -$75.27 million in Q1 2022, a 37.95% improvement from -$121.31 million in Q1 2021[11] - Cash and cash equivalents increased by 853.75% to $1.11 billion in Q1 2022, compared to a decrease of $147.72 million in Q1 2021[11] - Total cash and cash equivalents at the end of Q1 2022 reached $1.61 billion, a 211.28% increase from $518.57 million at the end of Q1 2021[11] Investment Activities - The company reported a significant decrease in investment cash inflow, which was $0 in Q1 2022 compared to $136.49 million in Q1 2021, due to the absence of matured financial products[11] - Investment cash outflow decreased by 41.77% to $94.85 million in Q1 2022 from $162.90 million in Q1 2021, primarily due to reduced purchases of financial products[11] - The total cash outflow from investing activities was 94,853,706.42, compared to 162,897,536.00 in the previous year, indicating a reduction in investment spending[29] - The company did not report any cash inflow from investment activities, contrasting with 136,493,132.66 in the previous year[29] Research and Development - Research and development expenses increased by 52.58% to ¥44,169,647.67, indicating a focus on enhancing innovation and product development[10] - Research and development expenses increased to ¥44,169,647.67, up from ¥28,948,546.80, reflecting a growth of 52.5%[25] - The company’s technology center was recognized as a national enterprise technology center, aiming to enhance its innovation capabilities[18] Acquisitions and Market Expansion - The company completed the acquisition of Shenzhen Tongce Testing Technology Co., Ltd., resulting in a long-term equity investment of ¥9,800,000.00[9] - The company acquired 70% of Shenzhen Tongce Testing Technology Co., Ltd. for RMB 49 million, enhancing its presence in the South China electronic testing market[18] - The company’s subsidiary in Inner Mongolia received approval to conduct clinical genetic testing, expanding its medical testing capabilities[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,261, with the largest shareholder holding 52.20% of the shares[13] - The company raised RMB 1,239,752,451.00 by issuing 22,418,670 shares at a price of RMB 55.30 each[17] Miscellaneous - The company plans to utilize up to RMB 700 million of idle funds for cash management without affecting investment plans[17] - The impact of exchange rate changes on cash and cash equivalents was a decrease of -7,529.88[29] - The first quarter report was not audited[30]

Financial Performance - The company's operating revenue for 2021 was approximately ¥2.007 billion, representing a 40.70% increase compared to ¥1.426 billion in 2020[16]. - The net profit attributable to shareholders for 2021 was approximately ¥220.29 million, a 34.54% increase from ¥163.73 million in 2020[16]. - The net profit after deducting non-recurring gains and losses was approximately ¥190.22 million, up 38.87% from ¥136.97 million in 2020[16]. - The total assets at the end of 2021 reached approximately ¥2.781 billion, a 31.59% increase from ¥2.113 billion at the end of 2020[16]. - The company reported a basic earnings per share of ¥1.6103 for 2021, reflecting a 12.12% increase from ¥1.4362 in 2020[16]. - The company achieved an operating income exceeding 2 billion RMB and a net profit surpassing 200 million RMB in 2021, with over 87,000 cooperative clients[61]. - The company achieved a total operating revenue of ¥2,006,685,260.63 in 2021, representing a year-on-year increase of 40.70% compared to ¥1,426,166,583.93 in 2020[70]. Dividend and Shareholder Policies - The company plans to distribute a cash dividend of 4.00 yuan per 10 shares (including tax) based on a total of 137,020,570 shares[3]. - The company has implemented a cash dividend policy to reward shareholders and enhance trust in corporate governance[116]. - The company has a profit distribution policy that ensures a minimum cash dividend ratio of 20% during profit distribution[161]. - The company plans to implement a cash dividend policy, with a minimum cash dividend ratio of 80% during profit distribution when in a mature stage without significant capital expenditure[198]. - The board will propose the specific dividend ratio according to the company's annual profit status and future funding plans[199]. Market Position and Strategy - The company aims to increase its market presence and expand its services in the life sciences and environmental safety sectors, responding to growing societal demands[10]. - The company has a strong market position in the testing industry, with over 50,000 testing institutions in China and an annual revenue exceeding ¥400 billion[25]. - The company is focused on expanding its capabilities in high-quality testing services to meet the growing market demand driven by new regulations and standards[25]. - The company aims to enhance its international cooperation and standardization efforts as part of its strategic growth initiatives[25]. - The company is positioned as a leader in the Chinese testing industry, with a broad market space and extensive service offerings[28]. Research and Development - The company has developed a robust R&D team and established various research institutions, ensuring continuous innovation in testing technologies[44]. - R&D investment amounted to ¥150,026,731.11 in 2021, representing 7.48% of total revenue, an increase from 6.90% in 2020[85]. - The number of R&D personnel increased by 41.07% to 948 in 2021, with a higher proportion of personnel holding bachelor's and master's degrees[85]. - The company plans to strengthen its research and development efforts by increasing investment in high-precision testing technologies and enhancing collaboration with domestic and international research institutions[111]. Operational Efficiency and Management - The company intends to implement a lean management approach to improve operational efficiency and profitability, focusing on standardized operations and cost reduction[112]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring accountability[125]. - The company has a structured remuneration system that aligns with market standards and individual contributions[144]. - The company has implemented a dual assessment mechanism for performance evaluation, focusing on both company-level and individual-level performance[166]. Corporate Governance - The company maintains an independent financial department, adhering to accounting standards and ensuring no interference from controlling shareholders[131]. - The company has a complete and independent asset management system, with no reliance on controlling shareholders for operational facilities[129]. - The company’s governance structure is in full compliance with legal and regulatory requirements, with no significant discrepancies noted[127]. - The independent directors, constituting over one-third of the board, have actively participated in major business decisions and provided impartial opinions on significant transactions[123]. Social Responsibility and Community Engagement - The company actively participates in national and local pollution prevention projects, contributing to carbon peak and carbon neutrality initiatives[179]. - The company has been recognized as an A-level institution for ecological environment monitoring credit evaluation[178]. - The company emphasizes the importance of corporate social responsibility and aims to enhance its brand image through community engagement and support for vulnerable groups[191]. - In 2021, the company donated to flood relief efforts in Zhengzhou and provided supplies to an elderly care facility in Changchun, showcasing its commitment to social responsibility[192]. Future Outlook and Growth Plans - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 15% to 18%[196]. - The company is considering strategic acquisitions to enhance its market position, with a budget of up to 300 million RMB for potential targets[196]. - The company plans to stabilize its stock price by implementing a buyback program, with a total buyback fund not exceeding 20% of the net proceeds from the new share issuance[197]. - The company plans to pursue strategic acquisitions to enhance its testing capabilities and expand its service offerings in specialized sectors[112].

Revenue and Profitability - The company's revenue for Q3 2021 reached ¥603,014,509.38, representing a year-on-year increase of 57.48%[3] - Net profit attributable to shareholders was ¥66,741,577.20, up 83.22% compared to the same period last year[3] - The net profit excluding non-recurring items was ¥62,281,513.52, reflecting a significant increase of 133.86% year-on-year[3] - The total operating revenue for the period reached CNY 1,341,708,482.18, a significant increase of 45.5% compared to CNY 922,716,199.43 in the previous period[27] - Net profit for the period was CNY 93,106,778.91, representing a 78.7% increase from CNY 52,104,378.16 in the same period last year[28] - Basic and diluted earnings per share were both CNY 0.6806, compared to CNY 0.4987 in the previous period, reflecting a growth of 36.5%[29] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥2,495,235,265.40, an increase of 18.08% from the end of the previous year[3] - The company's total liabilities reached CNY 609,859,916.77, up from CNY 292,559,689.56, indicating a growth of 108.5%[28] - The company's total current liabilities rose to CNY 481,325,250.73 from CNY 245,888,348.18, an increase of around 96%[25] - The total liabilities rose to 399,946,492.45 CNY from 292,559,689.56 CNY, with a notable increase in non-current liabilities attributed to lease liabilities[35] Cash Flow - The company’s cash flow from operating activities showed a negative net amount of ¥107,072,623.70, a significant decline of 8,701.94%[3] - Operating cash inflow totaled ¥1,067,183,500.62, an increase of 16.76% compared to ¥913,973,974.61 in the same period last year[10] - Operating cash outflow increased by 28.31% to ¥1,174,256,124.32 from ¥915,190,441.40 year-on-year[10] - The net cash flow from operating activities was -107,072,623.70 CNY, compared to -1,216,466.79 CNY in the previous year, indicating a significant increase in cash outflow[32] - The net cash flow from financing activities was -3,124,798.93 CNY, a decrease from 798,216,317.15 CNY in the previous year, reflecting a substantial reduction in financing inflows[32] Investments and Expenses - Research and development expenses increased by 51.83% to ¥103,034,597.59, indicating a commitment to innovation[9] - Investment cash inflow surged by 245.12% to ¥207,749,160.90, mainly from the redemption of financial products[10] - Investment cash outflow rose by 115.43% to ¥455,188,437.24, driven by capacity expansion and equipment purchases[10] - The total operating costs amounted to CNY 1,240,604,747.60, up 40.9% from CNY 880,485,699.42 in the prior period[28] Goodwill and Intangible Assets - The company acquired several medical testing laboratories, resulting in goodwill increasing by 7,838.53% to ¥27,347,012.74[7] - The company’s goodwill increased significantly to CNY 27,347,012.74 from CNY 344,484.50, indicating a substantial rise[25] - The company’s intangible assets rose to CNY 87,831,929.07 from CNY 73,559,814.11, an increase of about 19%[25] Operational Developments - The company completed the registration of the first grant of restricted stock under the 2021 incentive plan, with 357 participants subscribing to a total of 220,570 shares[20] - The company’s subsidiary, Suzhou Puni Medical Laboratory, was designated as a designated institution for COVID-19 testing in Suzhou[21] - The company’s subsidiary, Tianjin Puni Medical Laboratory, has been confirmed to have the capability to conduct COVID-19 nucleic acid testing[21] Financial Reporting and Audit - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[37] - The company is adjusting its financial statements in accordance with new leasing standards, which may affect future financial reporting and analysis[33]

Financial Performance - The company reported a revenue of 300 million RMB for the first half of 2021, representing a year-on-year increase of 20%[16] - The net profit attributable to shareholders for the same period was 50 million RMB, up 15% compared to the previous year[16] - The company achieved total revenue of CNY 738,693,972.80, representing a 36.85% increase compared to the same period last year[22] - Net profit attributable to shareholders reached CNY 26,365,201.71, marking a 68.17% year-on-year growth[22] - The net profit after deducting non-recurring gains and losses was CNY 11,495,753.39, a significant increase of 366.68% compared to the previous year[22] - The health and environmental segment generated revenue of CNY 611,932,176.24, up 43.65% year-on-year, driven by growth in carbon trading and environmental monitoring[30] - The consumer goods quality inspection segment reported revenue of CNY 78,760,253.39, reflecting an 11.04% increase from the previous year[30] - The electronic and safety compliance segment achieved revenue of CNY 21,356,387.24, a 13.65% increase, benefiting from stable growth in battery testing[30] - The company reported a net cash flow from operating activities of -CNY 95,308,154.71, a decline of 269.65% compared to the previous year[22] - The company reported a significant increase in income tax expenses, rising by 1182.42% to ¥5,387,834.70, due to higher tax provisions[65] - The company’s total comprehensive income for the first half of 2021 was ¥26,255,003.82, up from ¥15,673,093.84 in the same period last year[193] Market Expansion and Strategy - The company plans to expand its market presence by opening 10 new testing laboratories by the end of 2021[16] - The company anticipates a revenue growth of 15% for the second half of 2021, driven by increased demand in health and safety testing[16] - The company is exploring potential acquisitions to enhance its service offerings and market share[16] - The company plans to expand its business in biopharmaceutical R&D services, environmental reliability testing, and new energy vehicles[29] - The company is expanding its market presence by establishing new subsidiaries across various regions, including Hainan and Anhui, to enhance its service capabilities[94] - The company is actively expanding its user base and market share by targeting new growth areas and enhancing its service offerings[96] Research and Development - The company has invested 30 million RMB in R&D for new testing technologies, aiming to enhance service capabilities[16] - The group achieved significant performance improvement, with a 33.65% year-on-year increase in R&D expenses, emphasizing customer demand-driven innovation[52] - Research and development expenses rose by 33.65% to ¥55,157,894.45, reflecting increased investment in R&D personnel and materials[65] - The company has established a national postdoctoral research station to strengthen its R&D capabilities and support technological innovation[61] Operational Challenges and Risks - The management highlighted risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[4] - The company is addressing macroeconomic risks by closely monitoring economic fluctuations and expanding into new market segments to mitigate potential impacts on demand[96] - The competitive landscape in the testing industry is intensifying, with 48,919 testing institutions reported in China as of 2020, leading the company to enhance its operational capabilities and brand influence[99] - The company operates in a highly regulated third-party inspection and testing industry, which is subject to policy and industry standard changes that may impact operations[100] Corporate Governance and Social Responsibility - The company emphasizes its commitment to social responsibility and sustainable development while balancing stakeholder interests[112] - The company has established a comprehensive internal management control system to ensure financial stability and protect the interests of both shareholders and creditors[114] - The company actively participates in social welfare activities and has received honors such as "Excellent Enterprise" and "Public Welfare Love Award" for its contributions during the pandemic[123] - The company maintained compliance with environmental regulations and did not face any administrative penalties during the reporting period[111] Shareholder Information - The company did not distribute cash dividends or issue bonus shares for the first half of 2021[105] - A stock incentive plan was approved on June 15, 2021, allowing the company to grant restricted stock to 357 participants, totaling 220,570 shares[108] - The total share capital increased from 76,000,000 shares to 136,800,000 shares due to the 2020 profit distribution and capital reserve conversion plan[160] - The company distributed a cash dividend of 5.00 yuan per 10 shares (including tax) to all shareholders[160] - The largest shareholder, Song Wei, holds 71,505,000 shares, representing 52.27% of the total shares[166] Asset and Liability Management - Total assets at the end of the reporting period were CNY 2,216,663,630.79, an increase of 4.90% from the end of the previous year[22] - The company has made significant investments in fixed assets, which increased to CNY 777,290,688.78 from CNY 529,698,115.54, reflecting a growth of approximately 46.8%[184] - Total liabilities increased to CNY 407,816,171.57 from CNY 292,559,689.56, representing a growth of around 39.3%[185] - Owner's equity decreased slightly to CNY 1,808,847,459.22 from CNY 1,820,581,823.05, a decline of about 0.7%[186] Cash Flow and Investment Activities - Cash flow from operating activities showed a negative net amount of ¥95,308,154.71, a decline of 269.65% compared to the previous year, attributed to delayed customer payments[65] - The company received 186,000,000.00 CNY from investment recoveries, a significant increase from 46,000,000.00 CNY in the prior period[200] - Cash outflow for purchasing fixed assets and intangible assets was 206,726,531.06 CNY, compared to 116,623,971.02 CNY previously, reflecting increased capital expenditure[200] - Total cash inflow from investment activities was 187,605,970.75 CNY, significantly up from 46,169,639.04 CNY in the prior period[200]

Financial Performance - Revenue for Q1 2021 reached ¥311,601,470.04, an increase of 81.51% compared to ¥171,673,802.07 in the same period last year[7] - Net profit attributable to shareholders was -¥42,567,499.50, a slight improvement of 3.80% from -¥44,249,342.25 year-on-year[7] - Basic and diluted earnings per share improved by 59.91% to -¥0.3112 from -¥0.7763 in the same period last year[7] - The company reported a weighted average return on equity of -2.37%, an improvement of 2.74% from -5.11% in the previous year[7] - The total comprehensive income for Q1 2021 was a loss of CNY 42.57 million, slightly better than the loss of CNY 44.35 million in Q1 2020[47] Cash Flow - Net cash flow from operating activities was -¥121,307,300.07, representing a decline of 68.55% compared to -¥71,972,375.16 in the previous year[7] - Operating cash flow increased by 64.66% to CNY 299,943,668.26 in Q1 2021, primarily due to improved customer payment speed as the impact of the pandemic diminished[20] - The net cash flow from investment activities was CNY -26,404,403.34, reflecting increased outflows for equipment purchases and acquisitions[22] - The net increase in cash and cash equivalents was CNY -147,715,398.94, a decrease of 330.95% due to the combined effects of operating, investing, and financing activities[22] - The company reported a net cash outflow from financing activities of CNY 126,221,529.93, primarily due to bank loan repayments[22] Assets and Liabilities - Total assets increased by 3.78% to ¥2,193,059,161.06 from ¥2,113,141,512.61 at the end of the previous year[7] - Net assets attributable to shareholders decreased by 2.34% to ¥1,778,011,893.51 from ¥1,820,581,823.05 at the end of the previous year[7] - Total liabilities increased to CNY 415,047,267.55 from CNY 292,559,689.56, showing a growth of around 42%[38] - Current liabilities amounted to CNY 267,637,290.93, an increase from CNY 245,888,348.18, representing a rise of approximately 8.5%[38] - Owner's equity totaled CNY 1,778,011,893.51, down from CNY 1,820,581,823.05, indicating a decrease of about 2.3%[39] Operating Costs and Expenses - Operating costs for Q1 2021 were RMB 217.77 million, reflecting an increase of 80.09% from RMB 120.92 million in Q1 2020, primarily due to rising costs associated with increased revenue, including labor, consumables, and equipment depreciation[18] - The company’s management expenses rose by 42.84% to RMB 44.13 million, compared to RMB 30.89 million in the previous year, driven by increased depreciation and management support costs[19] - Total operating costs for Q1 2021 were approximately CNY 363.20 million, an increase from CNY 222.92 million in the same period last year, representing a growth of 63%[45] Investments and R&D - Research and development expenses for Q1 2021 amounted to RMB 28.95 million, a 59.04% increase from RMB 18.20 million in Q1 2020, reflecting the company's commitment to enhancing R&D capabilities[19] - The company plans to invest CNY 150,000,000 in the construction of a new headquarters and R&D center in Shandong[25] - The company has acquired three medical testing laboratories, which contributed to the increase in investment cash outflows[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,017[11] - The largest shareholder, Song Wei, holds 52.27% of the shares, totaling 39,725,000 shares[11] Other Financial Metrics - Non-recurring gains and losses amounted to ¥7,105,128.64, primarily from government subsidies and investment income[9] - The company incurred financial expenses of CNY -276,115.52, a significant decrease from CNY 1.45 million in the previous year, indicating improved financial management[45] - Other income for the quarter was CNY 9.95 million, compared to CNY 8.32 million in the same period last year, reflecting a growth of 19.6%[45]